Manhattan Research's ePharma Physician® study ranks the top online journals by physician visitation

Manhattan ResearchThe New England Journal of Medicine and American Family Physician rank as top online medical journals among U.S. primary care physicians, according to the just released ePharma Physician® v8.0 study by pharmaceutical and healthcare market research company Manhattan Research. Comparing the top online journals of 2007 to this year's batch, the Annals of Internal Medicine and American Family Physician have been two of the most successful publications in increasing online physician readership.

Reading online journals has been one of the fastest growing professional activities for physicians, growing at a double-digit rate over the past three years. The ePharma Physician® v8.0 survey found that physicians expect to increase their use of the Internet as a source of clinical news and information, making it critical for publications like the American College of Physicians Observer, the Cleveland Clinic, the Journal of General Internal Medicine, and others to maintain engaging online versions of their journals.

Top Online Journals among Physicians in 2008
Ranked by Number of U.S. Primary Care Physician Visitors

1. New England Journal of Medicine

2. American Family Physician

3. Annals of Internal Medicine

4. The Lancet

5. American Academy of Family Physicians

6. Journal of the American Medical Association

7. Family Practice Management

8. Cleveland Clinic

9. ACP (American College of Physicians) Observer

10. Journal of General Internal Medicine

Source: ePharma Physician® v8.0 (2008)

ePharma Physician® v8.0 Webcast
Marketers interested in learning more about the latest digital sales and professional marketing trends are invited to attend a webcast from Manhattan Research on August 26. The session is a must-attend event for healthcare and pharmaceutical marketers looking to effectively reach physician audiences through CRM, tech-enabled sales forces, interactive detailing, Web 2.0, pharmaceutical customer service portals, and other strategies. For qualified business accounts only.

Date & Time: Tuesday, August 26, 2008 at 11am and 3pm, EDT

Register Now: Enroll online at http://manhattanresearch.webex.com

About ePharma Physician® v8.0
ePharma Physician® v8.0 was conducted via online survey methodology in Q2 2008 among 1,681 online practicing U.S. physicians.

For seven consecutive years, the study has determined the leading online physician destinations based on the number of physician visitors as well as the content satisfaction of those who visit. In-depth analysis of top product and corporate pharmaceutical websites, health portals, online journal sites, specialty-specific sites, newsletters and society sites is available as part of the ePharma Physician® v8.0 advisory service.

ePharma Physician® v8.0 also includes the following specialist segments in the research: Allergy and Immunology, Cardiology (Cardiovascular Surgery and Interventional Cardiology), Dermatology, Emergency Medicine, Endocrinology, Family Medicine/General Practice, Gastroenterology, Infectious Disease or HIV physician, Internal Medicine, Nephrology, Neurology, OB/GYN, Oncology-Hematology & Medical, Ophthalmology, Pediatrics, Psychiatry, Pulmonology, Radiology, Rheumatology, Surgery (General and Orthopedic), and Urology.

Key Research Topics Covered

ePharma Physician® v8.0 research reveals insight into the following:

  • Interactive Detailing and Technology-Assisted Detailing
  • Top Online Resources
  • Web 2.0 Technologies
  • Email Use and Interest
  • Pharmaceutical Customer Service Portals
  • Top Product and Corporate Websites

ePharma Physician® v8.0 reveals the relevant market share and physician satisfaction for 300+ leading pharmaceutical product websites. A complete list of available product sites is available at www.manhattanresearch.com/products/Strategic_Advisory/ePP/default.aspx

Other Manhattan Research Products and Services
Manhattan Research conducts annual research studies among physicians and consumers, including Taking the Pulse®, Taking the Pulse® Europe, Taking the Pulse® Asia, Cybercitizen® Health, Cybercitizen® Health Europe, and ePharma Consumer®. Each study serves a unique purpose and focuses on different aspects of information technology adoption. Broad consumer and physician research is complemented by targeted analysis among more than 80 consumer therapeutic segments and 25 physician specialist segments.

Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory firm for pharmaceutical and healthcare companies. For more information, visit www.manhattanresearch.com.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...